The rationale behind designing and developing new aromatase inhibitors is to produce a drug molecule with higher clinical efficacy along with reduced side effects that could be beneficial in treating the postmenopausal women diagnosed with breast cancer [7]. Here, CYP19A1 is linked to breast carcinoma.